Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of RO7017773 in Autism Spectrum Disorder
2019-003524-20Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alogabat in Autism Spectrum Disorder (ASD) (3 arms), sponsored by Roche. Primary endpoint: Adaptive Behavior Composite change (Vineland III). Started Aug 2021; status: completed.
02
Drugs
alogabat
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2019-003524-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003524-20.